Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX)

REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for REGENXBIO and Dogwood Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1	1	8	0	2.70
Dogwood Therapeutics	1	0	1	0	2.00

REGENXBIO currently has a consensus price target of $27.50, indicating a potential upside of 228.16%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 468.72%. Given Dogwood Therapeutics’ higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than REGENXBIO.

Volatility and Risk

REGENXBIO has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Profitability

This table compares REGENXBIO and Dogwood Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-113.75%	-103.12%	-37.83%
Dogwood Therapeutics	N/A	-2,027.44%	-31.29%

Valuation & Earnings

This table compares REGENXBIO and Dogwood Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44 million	2.54	-$193.88 million	($3.76)	-2.23
Dogwood Therapeutics	N/A	N/A	-$34.26 million	($18.90)	-0.11

Dogwood Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 12.8% of REGENXBIO shares are owned by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

REGENXBIO beats Dogwood Therapeutics on 7 of the 13 factors compared between the two stocks.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.